×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ASND
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
08:31 am
asnd
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
Low
Report
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
11/29
01:30 am
asnd
Ascendis Pharma (ASND): Is There More Upside in the Valuation After Recent Momentum? [Yahoo! Finance]
Low
Report
Ascendis Pharma (ASND): Is There More Upside in the Valuation After Recent Momentum? [Yahoo! Finance]
11/28
10:23 pm
asnd
How the FDA's TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story [Yahoo! Finance]
Low
Report
How the FDA's TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story [Yahoo! Finance]
11/28
05:52 pm
asnd
How Analyst Views Are Shifting the Ascendis Pharma Story After Recent Yorvipath and Pipeline Updates [Yahoo! Finance]
Low
Report
How Analyst Views Are Shifting the Ascendis Pharma Story After Recent Yorvipath and Pipeline Updates [Yahoo! Finance]
11/26
09:17 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/25
07:09 pm
asnd
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia [Yahoo! Finance]
Medium
Report
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia [Yahoo! Finance]
11/25
06:15 pm
asnd
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
Low
Report
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
11/20
06:01 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
MISS
Report
3.1%
ascendis pharma a/s - american depositary shares
8/7/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
BEAT
Report
0.6%
ascendis pharma a/s - american depositary shares
5/1/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
MISS
Report
2.7%
ascendis pharma a/s - american depositary shares
2/12/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
BEAT
Report
13.0%
ascendis pharma a/s - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
05:07 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
Low
Report
Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
12/2
05:04 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
Low
Report
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
12/2
04:54 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: SPROGOE KENNETT
Low
Report
Form 144 Ascendis Pharma A/S Filed by: SPROGOE KENNETT
12/2
04:43 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN
Low
Report
Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN
12/1
02:31 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: SINGEL STINA
Low
Report
Form 144 Ascendis Pharma A/S Filed by: SINGEL STINA
11/26
06:05 am
asnd
Form 6-K Ascendis Pharma A/S For: Nov 25
Low
Report
Form 6-K Ascendis Pharma A/S For: Nov 25
11/14
12:19 pm
asnd
Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: T. Rowe Price Investment Management, Inc.
Medium
Report
Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: T. Rowe Price Investment Management, Inc.
11/14
11:54 am
asnd
Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: JANUS HENDERSON GROUP PLC
Medium
Report
Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: JANUS HENDERSON GROUP PLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/20
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Oppenheimer Holdings Inc. from $199.00 to $219.00. They now have an "outperform" rating on the stock.
9.1%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
TOP News Decliners
6/26
Form 6-K Ascendis Pharma A/S For: Jun 26
-9.8%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: